242 results on '"Cinciripini PM"'
Search Results
2. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates.
- Author
-
Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, St Aubin LB, Russ C, Flexible Quit Date Study Group, Rennard, Stephen, Hughes, John, Cinciripini, Paul M, Kralikova, Eva, Raupach, Tobias, Arteaga, Carmen, St Aubin, Lisa B, and Russ, Cristina
- Abstract
Introduction: Current smoking cessation guidelines recommend setting a quit date prior to starting pharmacotherapy. However, providing flexibility in the date of quitting may be more acceptable to some smokers. The objective of this study was to compare varenicline 1 mg twice daily (b.i.d.) with placebo in subjects using a flexible quit date paradigm after starting medication.Methods: In this double-blind, randomized, placebo-controlled international study, smokers of ≥10 cigarettes/day, aged 18-75 years, and who were motivated to quit were randomized (3:1) to receive varenicline 1 mg b.i.d. or placebo for 12 weeks. Subjects were followed up through Week 24. Subjects were instructed to quit between Days 8 and 35 after starting medication. The primary endpoint was carbon monoxide-confirmed continuous abstinence during Weeks 9-12, and a key secondary endpoint was continuous abstinence during Weeks 9-24.Results: Overall, 493 subjects were randomized to varenicline and 166 to placebo. Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9-12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7-9.4; p < .0001) and through 24 weeks follow-up (Weeks 9-24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6-7.5; p < .0001). Serious adverse events occurred in 1.2% varenicline (none were psychiatric) and 0.6% placebo subjects. Fewer varenicline than placebo subjects reported depression-related adverse events (2.3% vs. 6.7%, respectively).Conclusions: Varenicline 1 mg b.i.d. using a flexible quit date paradigm had similar efficacy and safety compared with previous fixed quit date studies. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
3. Pathways between socioeconomic status and modifiable risk factors among African American smokers.
- Author
-
Kendzor DE, Businelle MS, Mazas CA, Cofta-Woerpel LM, Reitzel LR, Vidrine JI, Li Y, Costello TJ, Cinciripini PM, Ahluwalia JS, and Wetter DW
- Subjects
CIGARETTE smokers ,SMOKING cessation ,SOCIAL status ,DISCRIMINATION in medical care ,HEALTH equity ,MEDICAL care - Abstract
Although socioeconomic status is a major contributing factor to health disparities, the mechanisms through which socioeconomic status influences health remain unclear. The purpose of the present study was to evaluate an a priori conceptual model of the pathways between socioeconomic status and modifiable health risk factors in a sample of 399 African Americans seeking smoking cessation treatment. A latent variable modeling approach was utilized to characterize the interrelationships among socioeconomic status, neighborhood disadvantage, social support, negative affect/perceived stress, and three specific modifiable risk factors (i.e., overweight/obesity, insufficient physical activity, at-risk drinking). Findings indicated that neighborhood disadvantage, social support, and negative affect/perceived stress function as pathways linking socioeconomic status and modifiable risk factors among African American smokers, and negative affect/perceived stress appears to play a key mediating role. Policy, community, and individual-level interventions may attenuate the impact of socioeconomic status on health by targeting intermediate psychosocial, environmental, and behavioral pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
4. Nicotine withdrawal in smokers with current depressive disorders undergoing intensive smoking cessation treatment.
- Author
-
Blalock JA, Robinson JD, Wetter DW, Schreindorfer LS, and Cinciripini PM
- Published
- 2008
- Full Text
- View/download PDF
5. The effects of stress and smoking on catecholaminergic and cardiovascular response.
- Author
-
Robinson JD and Cinciripini PM
- Abstract
In this study, the authors evaluated the combined impact of smoking and stress on catecholaminergic and cardiovascular reactivity in disease-free adult smokers. Smokers participated in 2 laboratory sessions, including a baseline and a mental-stressor phase (reaction time and mental math), once while smoking-deprived overnight and once while nondeprived. Nonsmoking controls also participated in an identical laboratory session, without the smoking manipulation. The authors obtained cardiovascular measures during each phase and measured catecholamine levels immediately after each phase. For nondeprived smokers, measures of norepinephrine, epinephrine, heart rate, and systolic blood pressure (SBP) were larger for the mental-stressor phase than for the baseline phase. The authors found no such increases for deprived smokers, and only SBP increased for controls from the baseline phase to the mental-stressor phase. The results suggest that ad lib smoking increases catecholamine and cardiovascular response to stress in smokers. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
6. Early cessation success or failure among women attempting to quit smoking: trajectories and volatility of urge and negative mood during the first postcessation week.
- Author
-
Cofta-Woerpel L, McClure JB, Li Y, Urbauer D, Cinciripini PM, Wetter DW, Cofta-Woerpel, Ludmila, McClure, Jennifer B, Li, Yisheng, Urbauer, Diana, Cinciripini, Paul M, and Wetter, David W
- Abstract
Aversive symptoms of abstinence from nicotine have been posited to lead to smoking relapse and research on temporal patterns of abstinence symptoms confirms this assumption. However, little is known about the association of symptom trajectories early after quitting with postcessation smoking or about the differential effects of tonic (background) versus phasic (temptation-related) symptom trajectories on smoking status. The current study examined trajectories of urge and negative mood among 300 women using the nicotine patch during the first postcessation week. Ecological momentary assessments collected randomly and during temptation episodes were analyzed using hierarchical linear modeling yielding four individual trajectory parameters: intercept (initial symptom level), linear slope (direction and rate of change), quadratic coefficient (curvature), and volatility (scatter). Early lapsers, who lapsed during the first postcessation week, exhibited more severe tonic urge and phasic negative mood immediately after quitting, and more volatile tonic and phasic urge compared to abstainers. Late lapsers, who were abstinent during the first week but lapsed by 1 month, exhibited more severe tonic urge immediately after quitting compared to abstainers. These results demonstrate the importance of early postcessation urge and negative affect and highlight the value of examining both tonic and phasic effects of abstinence from nicotine. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
7. Using eye tracking to evaluate the impact of smartphone-delivered attentional bias modification training for smokers.
- Author
-
Robinson JD, Cui Y, Engelmann JM, Kypriotakis G, and Cinciripini PM
- Abstract
Attentional bias modification (ABM) has been proposed to treat tobacco use disorder by reducing attentional bias (AB) to smoking-related cues. We sought to determine the extent to which AB to smoking cues, as measured by eye-tracking technology, was sensitive to multisession ABM among treatment-seeking adult smokers. The participants ( N = 203; 74 women) completed 13 days of daily ABM or sham training using a smartphone, followed by 8 weeks of nicotine replacement therapy and cessation counseling. ABM and sham training were administered using the modified dot-probe task (i.e., neutral cues probed 100% of the time) and the unmodified dot-probe task (i.e., cue types probed equally), respectively. Eye gaze dwell time proportions to paired presentations of smoking and neutral cues were measured at baseline, 1 day post-ABM training, and 8 weeks post-ABM training. At baseline, younger, more dependent smokers and those with higher smoking satisfaction scores looked longer at smoking cues than neutral ones. ABM training resulted in greater gaze preference for the smoking cues than sham training at 1 day posttraining. Gaze preference for smoking cues was positively associated with AB to smoking cues as measured by reaction time during the laboratory dot-probe assessment. At 8 weeks posttraining, gaze preference was not associated with any of the smoking outcome measures. These findings suggest that multisession ABM training resulted in changes in AB by increasing time spent looking at neutral compared with smoking cues in the short term. However, this effect was not sustained and was not associated with smoking behavior outcomes. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
- Published
- 2024
- Full Text
- View/download PDF
8. Co-action and changes in alcohol use during a smoking cessation attempt.
- Author
-
Vinci C, Lam CY, Etcheverry PE, Correa-Fernandez V, Cano MÁ, Cinciripini PM, and Wetter DW
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Black or African American, Counseling, Longitudinal Studies, Mexican Americans statistics & numerical data, Texas epidemiology, Tobacco Use Cessation Devices, White People, White, Hispanic or Latino, Alcohol Drinking epidemiology, Binge Drinking epidemiology, Smoking Cessation methods
- Abstract
Aims: Three smoking cessation studies (CARE, Break Free, Por Nuestra Salud [PNS]) were used to measure changes in average alcohol consumption, binge drinking and alcohol-related problems during a smoking cessation attempt and to explore co-action with smoking abstinence., Design: CARE and PNS were longitudinal cohort cessation studies; Break Free was a two-arm randomized clinical trial., Setting: Texas, USA., Participants: Participants were current smokers who were recruited from the community and received smoking cessation interventions. All participants received nicotine replacement therapy and smoking cessation counseling. CARE included 424 smokers (1/3 White, 1/3 African American and 1/3 Latino); Break Free included 399 African American smokers; PNS included 199 Spanish-speaking Mexican-American smokers., Measurements: Weekly alcohol consumption was collected multiple times pre and post-quit, and binge drinking and alcohol-related problems were collected at baseline and 26 weeks post-quit. Analyses included only those who indicated current alcohol use., Findings: Average alcohol consumption decreased from baseline to 26 weeks post-quit in CARE (F = 17.09, P < 0.001), Break Free (F = 12.08, P < 0.001) and PNS (F = 10.21, P < 0.001). Binge drinking decreased from baseline to 26 weeks post-quit in CARE (F = 3.94, P = 0.04) and Break Free (F = 10.41, P < 0.001) but not PNS. Alcohol-related problems decreased from baseline to 26 weeks post-quit in CARE (Chi-sq = 6.41, P = 0.010) and Break Free (Chi sq = 14.44, P = 0.001), but not PNS., Conclusions: Among current drinkers, alcohol use/problems appear to decrease during a smoking cessation attempt and remain low through 26 weeks after the quit attempt. Little evidence was found for co-action, with smoking abstainers and relapsers showing similar change in alcohol use/problems., (© 2024 Society for the Study of Addiction.)
- Published
- 2024
- Full Text
- View/download PDF
9. Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement: A Randomized Clinical Trial.
- Author
-
Cinciripini PM, Green CE, Shete S, Minnix JA, Robinson JD, Cui Y, Kim S, Kypriotakis G, Beneventi D, Blalock JA, Versace F, and Karam-Hage M
- Subjects
- Female, Humans, Male, Middle Aged, Double-Blind Method, Treatment Failure, White, Nicotine administration & dosage, Nicotine adverse effects, Nicotine therapeutic use, Nicotinic Agonists administration & dosage, Nicotinic Agonists therapeutic use, Smoking Cessation methods, Smoking Cessation Agents therapeutic use, Smoking Cessation Agents adverse effects, Smoking Cessation Agents administration & dosage, Varenicline therapeutic use, Varenicline administration & dosage, Varenicline adverse effects
- Abstract
Importance: Most people who smoke do not quit on their initial attempt., Objective: To determine the best subsequent strategy for nonabstinence following initial treatment with varenicline or combined nicotine replacement therapy (CNRT)., Design, Setting, and Participants: Using a double-blind, placebo-controlled, sequential multiple assignment randomized trial, 490 volunteers were randomized to receive 6 weeks of varenicline or CNRT. After 6 weeks, nonabstainers were rerandomized to continue, switch, or increase medication dosage for 6 additional weeks. The study was conducted from June 2015 through October 2019 in a Texas tobacco treatment clinic., Interventions: The initial treatment was 2 mg/d of varenicline or the combined replacement therapy of a 21-mg patch plus 2-mg lozenge. The rerandomized participants either continued with their initial therapies, switched between varenicline and CNRT, or increased dosages either to 3-mg or more of varenicline or to a 42-mg patch and lozenges. All received weekly brief counseling., Main Outcomes and Measures: Biochemically verified 7-day point prevalence abstinence at the end of treatment at 12 weeks., Results: The 490 randomized participants (210 female [43%], 287 non-Hispanic White [58%], mean age, 48.1 years) smoked an average of 20 cigarettes per day. After the first phase, 54 participants in the CNRT group were abstinent and continued their therapy; of the 191 who were not abstinent, 151 were rerandomized, and the 40 who did not return for rerandomization were assigned to continue their initial CNRT condition in phase 2. The end-of-treatment abstinence rate for the 191 phase 1 nonabstainers was 8% (95% credible interval [CrI], 6% to 10%) for the 90 (47%) who continued at the dosage condition, 14% (CrI, 10% to 18%) for the 50 (33%) who increased their dosage, and 14% (95% CrI, 10% to 18%) for the 51 (34%) who switched to varenicline (absolute risk difference [RD], 6%; 95% CrI, 6% to 11%) with more than 99% posterior probability that either strategy conferred benefit over continuing the initial dosage. After the first phase, 88 participants in the varenicline group were abstinent and continued their therapy; of the 157 who were not abstinent, 122 were rerandomized and 35 who did not return for rerandomization were assigned to continue with the varenicline condition. The end-of-treatment abstinence rate for the 157 phase 1 nonabstainers was 20% (95% CrI, 16% to 26%) for the 39 (32%) who increased their varenicline dosage, 0 (95% CrI, 0 to 0) for the 41 (34%) who switched CNRT, and 3% (95% CrI, 1% to 4%) for the 77 (49%) who were assigned to the continued varenicline condition (absolute RD, -3%; 95% CrI, -4% to -1%) with more than 99% posterior probability that continuing varenicline at the initial dosage was worse than switching to a higher dosage. Furthermore, increasing the varenicline dosage had an absolute RD of 18% (95% CrI, 13% to 24%) and a more than 99% posterior probability of conferring benefit. The secondary outcome of continuous abstinence at 6 months indicated that only increased dosages of the CNRT and varenicline provided benefit over continuation of the initial treatment dosages., Conclusions and Relevance: For individuals who smoked but did not achieve abstinence after treatment with varenicline, increasing the dosage enhanced abstinence vs continuing, whereas for nonabstainers initially treated with CNRT, a dosage increase or switch to varenicline enhanced abstinence and may be viable rescue strategies., Trial Registration: ClinicalTrials.gov Identifier: NCT02271919.
- Published
- 2024
- Full Text
- View/download PDF
10. Comparing the Fagerström Test and Heaviness of Smoking Index in Predicting Smoking Abstinence in Cancer Patients.
- Author
-
Rodríguez-Cano R, Kypriotakis G, Robinson JD, Karam-Hage M, Blalock JA, Minnix JA, Beneventi D, and Cinciripini PM
- Abstract
Introduction: People with cancer who smoke exhibit greater cigarette dependence than people without cancer who smoke, a crucial factor in smoking cessation. Research is limited on the predictive potential of the Fagerström Test for Cigarette Dependence (FTCD) and the Heaviness of Smoking Index (HSI) on smoking abstinence in cancer patients undergoing smoking cessation treatment., Methods: We analyzed data from 5,934 cancer patients seeking smoking cessation treatment at The University of Texas MD Anderson Cancer Center (female 52.08%; Mean age = 55.52, SD = 11.17). We evaluated the predictive accuracy of FTCD and HSI on abstinence at 3-, 6-, and 9-months from first consultation, and assessed the concordance between these tools in measuring cigarette dependence using Cohen's kappa test and different correlation and regression models. We also analyzed variations across sex at birth and race/ethnicity., Results: Both the FTCD and the HSI demonstrated comparable predictive accuracy for smoking cessation at all follow-ups, with neither showing high accuracy (Areas Under the Curve scores around 0.6). Concordance analysis revealed substantial agreement between FTCD and HSI scores (Cohen's kappa ~ 0.7), particularly at lower levels of dependence. However, this agreement varied by race, with reduced concordance observed in Non-Hispanic Blacks., Conclusions: Our results indicate that both the FTCD and HSI are effective tools for predicting smoking cessation in cancer patients, with the HSI offering a less burdensome assessment option. Nevertheless, the findings suggest the need for tailored approaches in assessing cigarette dependence that could predict smoking cessation more accurately, considering racial differences., Implications: The burden of assessing cigarette dependence in cancer care settings can be reduced by using the HSI instead of the FTCD. In addition, both instruments could be substantially interchanged and used for meta-analytic studies examining dependence and abstinence, but race/ethnicity should be considered., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco.)
- Published
- 2024
- Full Text
- View/download PDF
11. Examining the Association between Abstinence from Smoking and Healthcare Costs among Patients with Cancer.
- Author
-
Kypriotakis G, Kim S, Karam-Hage M, Robinson JD, Minnix JA, Blalock JA, Cui Y, Beneventi D, Kim B, Pan IW, Shih YT, and Cinciripini PM
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Aged, Cost-Benefit Analysis, Smoking economics, Smoking adverse effects, Smoking epidemiology, Smoking Cessation economics, Smoking Cessation statistics & numerical data, Neoplasms economics, Neoplasms epidemiology, Neoplasms therapy, Health Care Costs statistics & numerical data
- Abstract
Continuous tobacco use in patients with cancer is linked to substantial healthcare costs due to increased risks and complications, whereas quitting smoking leads to improved treatment outcomes and cost reductions. Addressing the need for empirical evidence on the economic impact of smoking cessation, this study examined the association between smoking cessation and healthcare cost utilization among a sample of 930 patients with cancer treated at The University of Texas MD Anderson Cancer Center's Tobacco Research and Treatment Program (TRTP). Applying conditional quantile regression and propensity scores to address confounding, our findings revealed that abstinence achieved through the TRTP significantly reduced the median cost during a 3-month period post-quitting by $1,095 [β = -$1,095, P = 0.007, 95% confidence interval (CI), = (-$1,886 to -$304)]. Sensitivity analysis corroborated these conclusions, showing a pronounced cost reduction when outlier data were excluded. The long-term accrued cost savings from smoking cessation could potentially offset the cost of participation in the TRTP program, underscoring its cost effectiveness. An important implication of this study is that by reducing smoking rates, healthcare systems can more efficiently allocate resources, enhance patient health outcomes, and lessen the overall cancer burden., Prevention Relevance: This study emphasizes the dual impact of smoking cessation programs in patients with cancer: quitting smoking and reducing healthcare costs. It highlights the importance of integrating cessation programs into cancer prevention strategies, ensuring both individual health benefits and broader, system-wide economic efficiencies. See related Spotlight, p. 197., (©2023 American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
12. Brief report: Characterization of electronic cigarette use among patients of a comprehensive cancer center.
- Author
-
Robinson JD, Kypriotakis G, Karam-Hage M, Cui Y, Beneventi D, Blalock JA, Minnix JA, and Cinciripini PM
- Subjects
- Adult, Humans, Tobacco Use, Surveys and Questionnaires, Vaping epidemiology, Electronic Nicotine Delivery Systems, Tobacco Products, Neoplasms epidemiology
- Abstract
Background and Objectives: We provide an initial characterization of e-cigarette use among adult cancer patients., Methods: Data were collected between November 2020 and August 2022 at a comprehensive cancer center., Results: Relatively few (4.59%) of the assessed patients (n = 47,117) reported ever using e-cigarettes. Over one-third of current e-cigarette users reported being current combustible cigarette users., Discussion and Conclusions: These data suggest that e-cigarette use is uncommon but associated with other tobacco use among adult cancer patients., Scientific Significance: This is among the first comprehensive surveys of adult cancer patient e-cigarette use that details the types of e-cigarette and other tobacco products used by this population., (© 2023 The American Academy of Addiction Psychiatry (AAAP).)
- Published
- 2024
- Full Text
- View/download PDF
13. Comparable cigarette consumption data collected using timeline follow-back and digital diary among treatment-seeking smokers.
- Author
-
Cui Y, Robinson JD, Kypriotakis G, Minnix JA, Green CE, Kim S, Karam-Hage M, and Cinciripini PM
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Cigarette Smoking therapy, Diaries as Topic, Mental Recall, Mobile Applications, Smartphone, Smoking Cessation methods, Smokers psychology
- Abstract
Objective: The timeline follow-back interview is a common method of collecting daily cigarette consumption (cigarettes per day [CPD]) in smoking research. However, it may be subject to recall bias due to its reliance on retrospective reports. The increasing ownership of smartphones allows researchers to administer app-based digital diaries (DD) to collect CPD, which is expected to have less recall bias. Several studies have compared these two methods and found a noticeable discrepancy between them. However, these studies have mainly focused on the time window when smokers were smoking ad libitum. In this study, we wanted to determine the comparability of these two methods when treatment-seeking smokers are attempting to quit smoking., Method: In a cessation trial, treatment-seeking smokers ( n = 251) reported their CPD using the timeline follow-back and DD methods over a 12-week treatment period. To evaluate the comparability, we used the Bland-Altman comparison approach for agreement, correlational analysis between CPD and biochemical measures, digit bias, and logistic regression for predicting abstinence., Results: We found that the two methods exhibited good agreement, and the agreement did not vary as a function of consumption levels. Consistent with this agreement, CPD data from both methods showed similar correlations with biochemical measures of smoking and predicted 6-month abstinence in a comparable fashion. Despite the agreement, the DD method appeared to be more precise by having a lower digit bias than the timeline follow-back method., Conclusions: Capturing smoking behavior using either TLFB or DD approaches yields similar data while smokers are attempting to quit smoking. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
- Published
- 2024
- Full Text
- View/download PDF
14. Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample.
- Author
-
Cinciripini PM, Wetter DW, Wang J, Yu R, Kypriotakis G, Kumar T, Robinson JD, Cui Y, Green CE, Bergen AW, Kosten TR, Scherer SE, and Shete S
- Subjects
- Humans, Smoking genetics, Bupropion therapeutic use, High-Throughput Nucleotide Sequencing, Repressor Proteins, Forkhead Transcription Factors, Nicotinic Agonists therapeutic use, Smoking Cessation psychology
- Abstract
Despite the large public health toll of smoking, genetic studies of smoking cessation have been limited with few discoveries of risk or protective loci. We investigated common and rare variant associations with success in quitting smoking using a cohort from 8 randomized controlled trials involving 2231 participants and a total of 10,020 common and 24,147 rare variants. We identified 14 novel markers including 6 mapping to genes previously related to psychiatric and substance use disorders, 4 of which were protective (CYP2B6 (rs1175607105), HTR3B (rs1413172952; rs1204720503), rs80210037 on chr15), and 2 of which were associated with reduced cessation (PARP15 (rs2173763), SCL18A2 (rs363222)). The others mapped to areas associated with cancer including FOXP1 (rs1288980) and ZEB1 (rs7349). Network analysis identified significant canonical pathways for the serotonin receptor signaling pathway, nicotine and bupropion metabolism, and several related to tumor suppression. Two novel markers (rs6749438; rs6718083) on chr2 are flanked by genes associated with regulation of bodyweight. The identification of novel loci in this study can provide new targets of pharmacotherapy and inform efforts to develop personalized treatments based on genetic profiles., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
15. The Effects of Scheduled Smoking Reduction and Precessation Nicotine Replacement Therapy on Smoking Cessation: Randomized Controlled Trial With Compliance.
- Author
-
Cinciripini PM, Minnix JA, Robinson JD, Kypriotakis G, Cui Y, Blalock JA, Lam CY, and Wetter DW
- Abstract
Background: Smoking remains a major public health problem, and it is important to provide a variety of efficacious and appealing options to encourage smokers to quit smoking. Scheduled smoking is a method of gradual reduction, preparing smokers to quit by systematically reducing cigarette consumption according to a predetermined schedule that increases the time between cigarette consumption. Gradual reduction may be preferred to abrupt quitting, but the efficacy of this cessation approach is unclear., Objective: This study aims, first, to evaluate the overall effectiveness of scheduled smoking alone, or in combination with precessation nicotine replacement therapy (NRT), versus standard NRT starting on the quit date with no prior smoking reduction and, second, to evaluate the impact of schedule compliance on the effectiveness of the intervention., Methods: A total of 916 participants recruited from the Houston metropolitan area were randomly assigned to 1 of the following 3 groups: scheduled smoking plus a precessation nicotine patch (n=306, 33.4%), scheduled smoking only with no precessation patch (n=309, 33.7%), and enhanced usual care (n=301, 32.9%) control. The primary abstinence outcomes were carbon monoxide-verified, self-reported, 7-day point prevalence abstinence at 2 and 4 weeks after the quit date. Unadjusted and adjusted logistic regression analyses were performed to evaluate the intervention effect. Scheduled smoking was implemented using a handheld device for 3 weeks before quitting. This trial was not registered because data collection began before July 1, 2005., Results: Results for the first aim showed no overall differences in abstinence among the 3 groups in both the unadjusted and adjusted models. However, the results for the second aim showed a clear effect on abstinence by schedule compliance at 2 and 4 weeks and 6 months after quitting (odds ratio [OR] 2.01, 95% CI 1.31-3.07), 4 weeks (OR 1.58, 95% CI 1.05-2.38), and 6 months (OR 1.68, 95% CI 1.04-2.64), with the differences at 2 and 4 weeks after quitting being the most robust. We also found that scheduled smoking was related to a reduction in nicotine withdrawal, negative affect, and craving when compared with the controls., Conclusions: Scheduled smoking, when combined with precessation use of NRT, can result in significantly higher abstinence rates than usual care (abrupt quitting with NRT), particularly in the early postquit phase (2 and 4 weeks after cessation) when smokers are compliant with the procedure. Scheduled smoking also produced a better overall quitting experience by reducing symptoms of nicotine withdrawal and craving, in comparison with usual care, which could encourage future quit attempts. Studies in this area should focus on the use of counseling or other methods to improve adherence., (©Paul M Cinciripini, Jennifer A Minnix, Jason D Robinson, George Kypriotakis, Yong Cui, Janice A Blalock, Cho Y Lam, David W Wetter. Originally published in JMIR Formative Research (https://formative.jmir.org), 20.06.2023.)
- Published
- 2023
- Full Text
- View/download PDF
16. Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial.
- Author
-
Yammine L, Verrico CD, Versace F, Webber HE, Suchting R, Weaver MF, Kosten TR, Alibhai H, Cinciripini PM, Lane SD, and Schmitz JM
- Subjects
- Humans, Overweight drug therapy, Tobacco Use Cessation Devices, Exenatide, Smokers, Nicotine, Weight Gain, Obesity drug therapy, Randomized Controlled Trials as Topic, Smoking Cessation, Prediabetic State drug therapy
- Abstract
Introduction: Obesity and smoking are the two leading causes of preventable death in the USA. Unfortunately, most smokers gain weight after quitting. Postcessation weight gain (PCWG) is frequently cited as one of the primary barriers to a quit attempt and a common cause of relapse. Further, excessive PCWG may contribute to the onset or progression of metabolic conditions, such as hyperglycaemia and obesity. The efficacy of the current treatments for smoking cessation is modest, and these treatments have no clinically meaningful impact on mitigating PCWG. Here, we outline a novel approach using glucagon-like peptide 1 receptor agonists (GLP-1RA), which have demonstrated efficacy in reducing both food and nicotine intake. This report describes the design of a double-blind, placebo-controlled, randomised clinical trial that evaluates the effects of the GLP-1RA exenatide as an adjunct to nicotine patches on smoking abstinence and PCWG., Methods and Analysis: The study will be conducted at two university-affiliated research sites in Houston, Texas, the UTHealth Center for Neurobehavioral Research on Addiction and Baylor College of Medicine Michael E. DeBakey VA Medical Centre. The sample will consist of 216 treatment-seeking smokers with pre-diabetes (haemoglobin A1c of 5.7%-6.4%) and/or overweight (body mass index of 25 kg/m
2 or above). Participants will be randomised (1:1) to receive subcutaneous injections of placebo or 2 mg exenatide, once weekly for 14 weeks. All participants will receive transdermal nicotine replacement therapy and brief smoking cessation counselling for 14 weeks. The primary outcomes are 4-week continuous abstinence and changes in body weight at the end of treatment. The secondary outcomes are (1) abstinence and changes in body weight at 12 weeks post end of treatment and (2) changes in neuroaffective responses to cigarette-related and food-related cues as measured by electroencephalogram., Ethics and Dissemination: The study has been approved by the UTHealth Committee for the Protection of Human Subjects (HSC-MS-21-0639) and Baylor College of Medicine Institutional Review Board (H-50543). All participants will sign informed consent. The study results will be disseminated via peer-reviewed publications and conference presentations., Trial Registration Number: NCT05610800., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2023
- Full Text
- View/download PDF
17. Towards neuromarkers for tailored smoking cessation treatments.
- Author
-
Versace F, Robinson JD, and Cinciripini PM
- Abstract
Vulnerability to compulsive drug use stems from dysregulated activity within the neural networks that underlie reward and executive functions. Empirical evidence suggests that a) attributing high motivational salience to drug-related stimuli leads to compulsive drug seeking and b) cognitive control deficits lead to compulsive drug taking. Noninvasive neuroimaging techniques enable brain activity monitoring during affective and cognitive processing and are paving the way to precision medicine for substance use disorders. Identifying robust neuromarkers of affective and cognitive dysregulation would allow clinicians to personalize treatments by targeting individual psychophysiological vulnerabilities. However, methodological choices have biased the field toward experimental paradigms that cannot optimally assess individual differences in the motivational salience of drug-related cues and in the ability to control drug-related decisions, choices which have hindered the identification of clinically relevant neuromarkers. Here, we show that once these shortcomings are amended, replicable neuromarkers of the tendency to attribute motivational salience to drug-related cues and the ability to control drug-related decisions emerge. While we use tobacco use disorder as a model, we also show that the methodological issues highlighted here are relevant to other disorders characterized by maladaptive appetitive behaviors., Competing Interests: Declarations of Interest: none
- Published
- 2023
- Full Text
- View/download PDF
18. Socio-economic status moderates within-person associations of risk factors and smoking lapse in daily life.
- Author
-
Potter LN, Schlechter CR, Nahum-Shani I, Lam CY, Cinciripini PM, and Wetter DW
- Subjects
- Adult, Humans, Smoking epidemiology, Tobacco Smoking, Risk Factors, Socioeconomic Factors, Economic Status, Smoking Cessation
- Abstract
Background and Aims: Individuals of lower socio-economic status (SES) display a higher prevalence of smoking and have more diffxiculty quitting than higher SES groups. The current study investigates whether the within-person associations of key risk (e.g. stress) and protective (self-efficacy) factors with smoking lapse varies by facets of SES., Design and Setting: Observational study using ecological momentary assessment to collect data for a 28-day period following a smoking quit attempt. Multi-level mixed models (i.e. generalized linear mixed models) examined cross-level interactions between lapse risk and protective factors and indicators of SES on smoking lapse., Participants: A diverse sample of 330 adult US smokers who completed a larger study examining the effects of race/ethnicity and social/environmental influences on smoking cessation., Measurements: Risk factors included momentary urge, negative affect, stress; protective factors included positive affect, motivation, abstinence self-efficacy; SES measures: baseline measures of income and financial strain; the primary outcome was self-reported lapse., Findings: Participants provided 43 297 post-quit observations. Mixed models suggested that income and financial strain moderated the effect of some risk factors on smoking lapse. The within-person association of negative [odds ratio (OR) = 0.967, 95% CI= 0.945, 0.990, P < 0.01] and positive affect (OR = 1.023, 95% CI = 1.003, 1.044, P < 0.05) and abstinence self-efficacy (OR = 1.020, 95% CI = 1.003, 1.038, P < 0.05) on lapse varied with financial strain. The within-person association of negative affect (OR = 1.005, 95% CI = 1.002, 1.008, P < 0.01), motivation (OR = 0.995, 95% CI = 0.991, 0.999, P < 0.05) and abstinence self-efficacy (OR = 0.996, 95% CI = 0.993, 0.999, P < 0.01) on lapse varied by income. The positive association of negative affect with lapse was stronger among individuals with higher income and lower financial strain. The negative association between positive affect and abstinence self-efficacy with lapse was stronger among individuals with lower financial strain, and the negative association between motivation and abstinence self-efficacy with lapse was stronger among those with higher income. The data were insensitive to detect statistically significant moderating effects of income and financial strain on the association of urge or stress with lapse., Conclusion: Some risk factors (e.g. momentary negative affect) exert a weaker influence on smoking lapse among lower compared to higher socio-economic status groups., (© 2022 Society for the Study of Addiction.)
- Published
- 2023
- Full Text
- View/download PDF
19. A protocol for a cluster randomized trial of care delivery models to improve the quality of smoking cessation and shared decision making for lung cancer screening.
- Author
-
Lowenstein LM, Shih YT, Minnix J, Lopez-Olivo MA, Maki KG, Kypriotakis G, Leal VB, Shete SS, Fox J, Nishi SP, Cinciripini PM, and Volk RJ
- Subjects
- Aged, Humans, United States, Decision Making, Shared, Early Detection of Cancer methods, Medicare, Delivery of Health Care, Decision Making, Randomized Controlled Trials as Topic, Smoking Cessation methods, Lung Neoplasms diagnosis
- Abstract
Background: Patients eligible for lung cancer screening (LCS) are those at high risk of lung cancer due to their smoking histories and age. While screening for LCS is effective in lowering lung cancer mortality, primary care providers are challenged to meet beneficiary eligibility for LCS from the Centers for Medicare & Medicaid Services, including a patient counseling and shared decision-making (SDM) visit with the use of patient decision aid(s) prior to screening., Methods: We will use an effectiveness-implementation type I hybrid design to: 1) identify effective, scalable smoking cessation counseling and SDM interventions that are consistent with recommendations, can be delivered on the same platform, and are implemented in real-world clinical settings; 2) examine barriers and facilitators of implementing the two approaches to delivering smoking cessation and SDM for LCS; and 3) determine the economic implications of implementation by assessing the healthcare resources required to increase smoking cessation for the two approaches by delivering smoking cessation within the context of LCS. Providers from different healthcare organizations will be randomized to usual care (providers delivering smoking cessation and SDM on site) vs. centralized care (smoking cessation and SDM delivered remotely by trained counselors). The primary trial outcomes will include smoking abstinence at 12-weeks and knowledge about LCS measured at 1-week after baseline., Conclusion: This study will provide important new evidence about the effectiveness and feasibility of a novel care delivery model for addressing the leading cause of lung cancer deaths and supporting high-quality decisions about LCS., Gov Protocol Registration: NCT04200534 TRIAL REGISTRATION: ClinicalTrials.govNCT04200534., Competing Interests: Declaration of Competing Interest Dr. Cinciripini served on the scientific advisory board of Pfizer Pharmaceuticals, conducted educational talks sponsored by Pfizer on smoking cessation (2006–2008), and has received grant support from Pfizer., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
20. Electrophysiological normative responses to emotional, neutral, and cigarette-related images.
- Author
-
Versace F, Sambuco N, Deweese MM, and Cinciripini PM
- Subjects
- Female, Humans, Adolescent, Young Adult, Adult, Middle Aged, Aged, Male, Evoked Potentials physiology, Arousal physiology, Motivation, Photic Stimulation, Emotions physiology, Tobacco Products
- Abstract
To create reproducible emotional probes, affective scientists rely on sets of standardized pictures that are normed using subjective ratings of valence and emotional arousal. However, when emotional responses are investigated using neurophysiological measures, it might be more appropriate to select pictures integrating information from normative subjective reports and normative neurophysiological responses. Here, we provide electrophysiological normative responses for 323 emotional pictures (215 from the IAPS) covering a wide range of categories (erotica, romantic, appetizing foods, landscapes, people engaged in mundane activities, household objects, disgusting objects, accidents, sad people, violence, mutilations, and cigarette-related contents). Event-related potentials (ERPs) and subjective ratings of pleasure and emotional arousal were collected from 763 individuals (52% females, 41% white) aged between 18 and 65 (mean = 43). For each image, the mean amplitude of the late positive potential (LPP, an electrophysiological index of motivational relevance) and the mean subjective ratings of valence and arousal were calculated. We validated our procedure by showing that the subjective ratings of valence and arousal from this sample were highly correlated to the IAPS' published norms (Pearson r = .97 for pleasure and r = .82 for emotional arousal). LPP responses and subjective ratings of emotional arousal also were correlated (Pearson r = .61), but some categories reported being significantly more arousing than neutral (i.e., food, landscapes, and unpleasant objects) did not evoke LPPs significantly different from those evoked by neutral pictures. Researchers interested in probing the brain's affective systems can use these electrophysiological normative responses to create emotional probes that evoke reliable neuroaffective responses., (© 2022 Society for Psychophysiological Research.)
- Published
- 2023
- Full Text
- View/download PDF
21. Smoking Cessation, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
- Author
-
Shields PG, Bierut L, Arenberg D, Balis D, Cinciripini PM, Davis J, Edmondson D, Feliciano J, Hitsman B, Hudmon KS, Jaklitsch MT, Leone FT, Ling P, McCarthy DE, Ong MK, Park ER, Prochaska J, Sandoval AJ, Sheffer CE, Spencer S, Studts JL, Tanvetyanon T, Tindle HA, Tong E, Triplette M, Urbanic J, Videtic G, Warner D, Whitlock CW, McCullough B, and Darlow S
- Subjects
- Humans, Smoking, Medical Oncology, Smoking Cessation, Tobacco Products, Neoplasms
- Abstract
Although the harmful effects of smoking after a cancer diagnosis have been clearly demonstrated, many patients continue to smoke cigarettes during treatment and beyond. The NCCN Guidelines for Smoking Cessation emphasize the importance of smoking cessation in all patients with cancer and seek to establish evidence-based recommendations tailored to the unique needs and concerns of patients with cancer. The recommendations contained herein describe interventions for cessation of all combustible tobacco products (eg, cigarettes, cigars, hookah), including smokeless tobacco products. However, recommendations are based on studies of cigarette smoking. The NCCN Smoking Cessation Panel recommends that treatment plans for all patients with cancer who smoke include the following 3 tenets that should be done concurrently: (1) evidence-based motivational strategies and behavior therapy (counseling), which can be brief; (2) evidence-based pharmacotherapy; and (3) close follow-up with retreatment as needed.
- Published
- 2023
- Full Text
- View/download PDF
22. Smoking abstinence and cessation-related outcomes one month after an immediate versus gradual reduction in nicotine content of cigarettes.
- Author
-
Klemperer EM, Luo X, Jensen J, al'Absi M, Cinciripini PM, Robinson JD, Drobes DJ, McClernon J, Strasser AA, Strayer LG, Vandrey R, Benowitz NL, Donny EC, and Hatsukami DK
- Subjects
- United States, Humans, Nicotine adverse effects, Nicotine analysis, Smoking, Smoking Cessation methods, Tobacco Products, Tobacco Use Disorder
- Abstract
The United States Food and Drug Administration has the authority to reduce the nicotine content in cigarettes to minimal or non-addictive levels and could do so immediately or gradually over time. A large clinical trial compared the two approaches. This secondary analysis assesses abstinence and cessation-related outcomes one month after the trial concluded, when participants no longer had access to very low nicotine content (VLNC) research cigarettes. Smokers not interested in quitting (N = 1250) were recruited for the parent trial from 2014 to 2016 across 10 sites throughout the US and randomized to a 20-week study period during which they immediately switched to VLNC cigarettes, gradually transitioned to VLNC cigarettes with five monthly dose reductions, or smoked normal nicotine research cigarettes (control). At the one-month follow-up, both immediate and gradual reduction resulted in greater mean cigarette-free days (4.7 and 4.6 respectively) than the control group (3.2, both p < .05). Immediate reduction resulted in fewer mean cigarettes per day (CPD = 10.3) and lower Fagerström Test for Cigarette Dependence (FTCD = 3.7) than the gradual (CPD = 11.7, p = .001; FTCD = 3.8, p = .039) and control (CPD = 13.5, p < .001; FTCD = 4.0, p < .001) groups. Compared to controls, gradual reduction resulted in reduced CPD (p = .012) but not FTCD (p = .13). Differences in CO-verified 7-day point-prevalence abstinence were not significant. Findings demonstrate that switching to VLNC cigarettes resulted in reduced smoking and nicotine dependence severity that was sustained for at least a month after the VLNC trial period in smokers who were not interested in cessation. The greatest harm reduction endpoints were observed in those who immediately transitioned to VLNC cigarettes., Competing Interests: Declaration of Competing Interest EMK, XL, JJ, MA PMC, JDR, LGS, ECD, and DKH have nothing to disclose. DJD has served as a paid expert witness in litigation against tobacco companies. JM has provided consulting and marketing research services to GlaxoSmithKline Consumer Healthcare on smoking cessation behavioral support programs. AAS has received grant support through the Pfizer GRAND grant funding program. RV has received compensation for consulting or scientific advisory board service to Canopy Health Innovations Inc., MyMD Pharmaceuticals, Mira Therapeutics Inc., Syqe Medical Ltd., Radicle Science LLC, and WebMD. NLB serves as a consultant to Pfizer and Achieve Life Sciences, companies that market or are developing smoking cessation medications, and has been a paid expert witness in litigation against tobacco companies., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
23. Sustained reduction of attentional bias to smoking cues by smartphone-delivered attentional bias modification training for smokers.
- Author
-
Robinson JD, Cui Y, Linares Abrego P, Engelmann JM, Prokhorov AV, Vidrine DJ, Shete S, and Cinciripini PM
- Subjects
- Humans, Cues, Smokers, Smartphone, Tobacco Use Cessation Devices, Smoking therapy, Attentional Bias physiology, Smoking Cessation psychology, Substance Withdrawal Syndrome
- Abstract
Objective: Cigarette smoking is thought to be at least partially maintained by the attentional bias (AB) toward smoking cues that develops as a consequence of drug dependence. This study evaluated the impact of smartphone-delivered, in-home attentional bias modification (ABM) to reduce AB to smoking cues and to reduce smoking behavior and withdrawal-related symptoms when used as an adjunct to conventional smoking cessation treatment., Method: Participants ( N = 246) were treatment-seeking smokers who completed up to 13 days of either ABM designed to train attention away from smoking cues, using a modified dot-probe task, or sham training, followed by 8 weeks of nicotine replacement therapy and counseling. Outcomes measured at baseline, 1-day post-ABM training, and 8 weeks post-ABM training included AB to smoking images and words using the dot-probe and smoking Stroop tasks, respectively, along with cigarettes per day, craving, and smoking abstinence., Results: We found that ABM training reduced AB to smoking stimuli on both the dot-probe task, η
p ² = 0.056, 90% CI [0.024, 0.097], and the smoking Stroop task, ηp ² = 0.017, 90% CI [0.002, 0.044], up to 8 weeks after ABM training when covarying for baseline response, but did not concurrently decrease smoking behavior or craving., Conclusions: Thirteen days of smartphone-delivered ABM training, as an adjunct to smoking cessation treatment, reduced AB to both modality-specific and cross-modality smoking cues but did not impact smoking-related behavior. While ABM can reduce AB to smoking cues across modalities, it is unclear whether it has therapeutic potential as an adjunct to conventional smoking cessation therapy. (PsycInfo Database Record (c) 2022 APA, all rights reserved).- Published
- 2022
- Full Text
- View/download PDF
24. An ecological momentary assessment study of outcome expectancies and smoking lapse in daily life.
- Author
-
Potter LN, Schlechter CR, Shono Y, Lam CY, Cinciripini PM, and Wetter DW
- Subjects
- Adult, Humans, Smokers, Smoking, Tobacco Smoking, Ecological Momentary Assessment, Smoking Cessation
- Abstract
Objective: Outcome expectancies have been identified as key components of behavior change. Expectancies related to affect control are hypothesized to play an important role in smoking cessation, such that smokers may be more likely to lapse if they believe they can control their affect by smoking and less likely if they believe they can control their affect by means other than smoking. However, little is known about whether real-time, real-world changes in affect control expectancies influence smoking lapse during a quit attempt., Methods: A diverse sample (N = 369) of adult smokers completed ecological momentary assessment of smoking expectancies and lapse for 28 days following a quit attempt. Multilevel logistic regression was used to examine whether the difference score of positive smoking outcome expectancies (the belief that smoking would improve mood) minus positive coping outcome expectancies (the belief that something other than smoking would improve mood) was related to smoking lapse in daily life., Results: There was a significant within-person association between the expectancies difference score and lapse likelihood. When the difference score was 1 unit above a person's typical level, odds of lapse increased by 18.65 % (β = 0.174, SE = 0.024, p < .0001, OR = 1.189, 95 % CI [1.135, 1.247])., Conclusion: Smokers undergoing a quit attempt were more likely to lapse in moments when the difference in the belief that smoking would improve their mood minus the belief that something other than smoking would improve their mood was larger. This work has relevance for tailoring interventions to both cultivate positive coping outcome expectancies and reduce smoking outcome expectancies, and informs theoretical models about the dynamic nature of outcome expectancies., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
25. Modern Perioperative Practices May Mitigate Effects of Continued Smoking Among Lung Cancer Patients.
- Author
-
Bayley EM, Zhou N, Mitchell KG, Antonoff MB, Mehran RJ, Rice DC, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Cinciripini PM, Karam-Hage M, Roth JA, and Hofstetter WL
- Subjects
- Humans, Incidence, Neoplasm Recurrence, Local, Postoperative Complications epidemiology, Postoperative Complications prevention & control, Smoking adverse effects, Carcinoma, Non-Small-Cell Lung surgery, Lung Neoplasms diagnosis, Lung Neoplasms surgery, Smoking Cessation methods
- Abstract
Background: Although smokers are at an increased risk for postoperative pulmonary complications after thoracic surgery, the relationship between cessation timing and postoperative pulmonary complications has not been explored in an era of enhanced recovery protocols and active tobacco cessation programs. Because a strong preference exists among thoracic surgeons to delay surgery to continued smokers, we sought to evaluate this relationship in a modern era., Methods: Patients undergoing lung resection for a diagnosis of non-small cell lung cancer from 2012 to 2017 were identified. Multivariable logistic regression was used to evaluate preoperative tobacco cessation timing to determine the impact on postoperative pulmonary complications., Results: In all, 1038 ever smokers were identified. Patients were current smokers in 30 (3%) instances, and among former smokers, the preoperative cessation interval was 0 to 14 days in 10% (104), more than 14 days to 1 month in 6% (62), more than 1 month to 1 year in 18% (189), more than 1 to 5 years in 10% (107), and more than 5 years in 53% (546). Pulmonary complications occurred in 269 patients (26%). Multivariable analysis revealed that no group of recent or long-term quitters had superior outcomes in terms of pulmonary complications when evaluating various periods of abstinence in comparison with continued smokers and active quitters., Conclusions: In an era of enhanced recovery protocols, minimally invasive surgery, and active tobacco cessation programs that may help patients to cut back, our data do not support the practice of delaying or denying surgery to patients who have difficulty quitting completely. Perioperative cessation counseling should be aimed at long-term benefits, including reduction of disease recurrence and secondary malignancies., (Copyright © 2022 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
26. National Cancer Institute Smoking Cessation at Lung Examination Trials Brief Report: Baseline Characteristics and Comparison With the U.S. General Population of Lung Cancer Screening-Eligible Patients.
- Author
-
Meza R, Jeon J, Jimenez-Mendoza E, Mok Y, Cao P, Foley KL, Chiles C, Ostroff JS, Cinciripini PM, Minnix J, Rigotti NA, Haas JS, Taylor K, Williams RM, Toll BA, and Joseph AM
- Abstract
Introduction: The National Cancer Institute Smoking Cessation at Lung Examination (SCALE) Collaboration includes eight clinical trials testing smoking cessation interventions delivered with lung cancer screening (LCS). This investigation compared pooled participant baseline demographic and smoking characteristics of seven SCALE trials to LCS-eligible smokers in three U.S. nationally representative surveys., Methods: Baseline variables (age, sex, race, ethnicity, education, income, cigarettes per day, and time to the first cigarette) from 3614 smokers enrolled in SCALE trials as of September 2020 were compared with pooled data from the Tobacco Use Supplement-Current Population Survey (2018-2019), National Health Interview Survey (2017-2018), and Population Assessment of Tobacco and Health (wave 4, 2016-2017) using the U.S. Preventive Services Task Force 2013 (N = 4803) and 2021 (N = 8604) LCS eligibility criteria., Results: SCALE participants have similar average age as the U.S. LCS-eligible smokers using the 2013 criteria but are 2.8 years older using the 2021 criteria ( p < 0.001). SCALE has a lower proportion of men, a higher proportion of Blacks, and slightly higher education and income levels than national surveys ( p < 0.001). SCALE participants smoke an average of 17.9 cigarettes per day (SD 9.2) compared with 22.4 (SD 9.3) using the 2013 criteria and 19.6 (SD 9.7) using the 2021 criteria ( p < 0.001). The distribution of time to the first cigarette differs between SCALE and the national surveys ( p < 0.001), but both indicate high levels of nicotine dependence., Conclusions: SCALE participants smoke slightly less than the LCS-eligible smokers in the general population, perhaps related to socioeconomic status or race. Other demographic variables reveal small but statistically significant differences, likely of limited clinical relevance with respect to tobacco treatment outcomes. SCALE trial results should be applicable to LCS-eligible smokers from the U.S. population., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
27. The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial.
- Author
-
Cinciripini PM, Kypriotakis G, Green C, Lawrence D, Anthenelli RM, Minnix J, Blalock JA, Beneventi D, Morris C, and Karam-Hage M
- Subjects
- Bupropion adverse effects, Depression, Female, Humans, Male, Middle Aged, Polyesters, Smokers, Tobacco Use Cessation Devices adverse effects, Treatment Outcome, Varenicline adverse effects, Depressive Disorder, Major drug therapy, Depressive Disorder, Major etiology, Smoking Cessation psychology
- Abstract
Importance: Improving treatment outcomes for smokers with major depressive disorder (MDD) can have significant public health implications., Objective: To evaluate the safety and efficacy of smoking cessation pharmacotherapy among smokers with MDD., Design: Secondary analysis of a randomized, double-blind, active- (nicotine patch) and placebo-controlled trial of 12 weeks of either varenicline or bupropion with a 12-week follow-up., Participants: Community volunteers 18-75 years of age; smoke 10+ cigarettes/day; with clinically stable MDD (N = 2635) or no psychiatric disorder (N = 4028), from 140 sites in 16 countries., Intervention: Twelve weeks of pharmacotherapy (placebo [PLA], nicotine replacement therapy [NRT], bupropion [BUP], varenicline [VAR]) plus brief cessation counseling., Measure(s): Primary safety outcome: the occurrence of ≥1 treatment-emergent, moderate to severe neuropsychiatric adverse event (NPSAE). Primary efficacy outcome: biochemically confirmed continuous abstinence (CA) during the final 4 weeks of treatment (Weeks 9-12)., Results: A total of 6653 participants (56% female; 39% MDD) ~47 years old. Risk of NPSAEs did not differ by medication for MDD. MDD had higher risk (p < .0001) for NPSAEs than the NPC. Efficacy (6653; intent-to-treat): CA rates for MDD versus NPC respectively were 31.2% versus 38.0% VAR; 23.0% versus 26.1% BUP; 22.6% versus 26.4% NRT; and 13.4% versus 13.7% PLA but no differential treatment effect was noted within the cohorts. All active treatments differed from PLA but VAR showed the largest effect., Conclusions: Results suggest that for MDD smokers, inclusive of those with recurrent episode, varenicline plus counseling may be the best pharmacological option for the treatment of smoking given its greater efficacy effect size and similar risk of NPSAEs., Trial Registration: ClinicalTrials.gov Identifier: NCT01456936. https://clinicaltrials.gov/ct2/show/NCT01456936., (© 2022 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
28. Bupropion XL and SR have similar effectiveness and adverse event profiles when used to treat smoking among patients at a comprehensive cancer center.
- Author
-
Robinson JD, Karam-Hage M, Kypriotakis G, Beneventi D, Blalock JA, Cui Y, Gonzalez R, Tayar J, Chaftari P, and Cinciripini PM
- Subjects
- Bupropion adverse effects, Humans, Smoking adverse effects, Smoking drug therapy, Tobacco Smoking, Tobacco Use Cessation Devices adverse effects, Neoplasms drug therapy, Smoking Cessation
- Abstract
Background and Objectives: Bupropion extended-release (XL; once-daily dosing) has equal efficacy with the sustained-release (SR) formulation (twice-daily dosing) for treating depression, but no studies have compared the two formulations for the treatment of smoking. In a naturalistic open-label study, we compared the effectiveness and the adverse event profiles of XL and SR in treating cancer patients for smoking., Methods: Cancer patients (N = 648) were prescribed bupropion XL (n = 454) or SR (n = 194) alone or in combination with nicotine replacement therapy (NRT) for treating smoking from September 2006 to December 2017. We analyzed 7-day point prevalence abstinence at end-of-treatment (EOT; 3 months postmedication initiation) and evaluated for noninferiority. We also analyzed the adverse event profile differences between the medications., Results: There were no significant differences in abstinent rates at EOT between bupropion XL and SR when using intent-to-treat models, regardless of concomitant NRT. XL demonstrated noninferiority in treatment efficacy compared to SR when excluding those on combined treatment with NRT. Further, there were no significant differences in spontaneously reported adverse events between XL and SR., Conclusions: Our data did not reveal a difference between bupropion XL and SR formulations in terms of effectiveness or adverse event profiles among cancer patients prescribed bupropion alone or in combination with NRTs to quit smoking., Scientific Significance: In this first published direct comparison of their effectiveness and adverse event profiles, we found that bupropion XL is likely therapeutically equivalent to bupropion SR when treating smoking among cancer patients, and produces similar side effects., (© 2022 American Academy of Addiction Psychiatry.)
- Published
- 2022
- Full Text
- View/download PDF
29. The Impact of Treatment for Smoking on Breast Cancer Patients' Survival.
- Author
-
Singareeka Raghavendra A, Kypriotakis G, Karam-Hage M, Kim S, Jizzini M, Seoudy KS, Robinson JD, Barcenas CH, Cinciripini PM, Tripathy D, and Ibrahim NK
- Abstract
Background: Smoking negatively affects overall survival after successful breast cancer (BC) treatment. We hypothesized that smoking cessation would improve survival outcomes of BC patients who were smokers at the time of diagnosis., Methods: This was a retrospective analysis of self-identified smokers with BC treated at The University of Texas MD Anderson Cancer Center. Patient demographics, date of diagnosis, tumor stage, tobacco treatment program (TP) participation, and time to death were extracted from our departmental databases and institutional electronic health records. We examined associations between tobacco abstinence status and survival using survival models, with and without interactions, adjusted for personal characteristics and biomarkers of disease., Results: Among all 31,069 BC patients treated at MD Anderson between 2006 and 2017, we identified 2126 smokers (6.8%). From those 2126 self-identified smokers, 665 participated in the TP, reporting a conservative estimate of 31% abstinence (intent-to-treat) 9 months into the program. Patients without reported follow-up abstinence status (including TP and non-TP participants) were handled in the analyses as smokers. Survival analysis controlled for multiple factors, including disease characteristics and participation in the TP, indicated that abstainers were more likely to be alive with no evidence of disease compared to non-abstainers (HR, 0.593; 95% CI, 0.386-0.911; p = 0.017)., Conclusion: Our results suggest that quitting smoking is associated with improved survival among BC patients who were smokers at time of diagnosis across all tumor stages. Comprehensive approaches for smoking cessation in patients diagnosed with BC may prolong survival when started as early as the time of diagnosis.
- Published
- 2022
- Full Text
- View/download PDF
30. Topiramate decreases the salience of motivationally relevant visual cues among smokers with alcohol use disorder.
- Author
-
Robinson JD, Cui Y, Karam-Hage M, Kypriotakis G, Versace F, Ait-Daoud Tiouririne N, Anthenelli RM, and Cinciripini PM
- Subjects
- Alcohol Drinking, Cues, Humans, Topiramate therapeutic use, Alcoholism drug therapy, Alcoholism psychology, Smokers psychology
- Abstract
Background: There is preliminary evidence that the anticonvulsant topiramate increases the likelihood of both smoking and alcohol abstinence among smokers with alcohol use disorder (AUD), but its therapeutic mechanism has not been determined. We used event-related potentials (ERPs) to evaluate topiramate's effect on the salience of drug-related, emotional, and neutral pictorial cues to identify whether one of its potential therapeutic mechanisms involves reduction of the salience of motivationally relevant cues., Methods: Participants enrolled in a multisite clinical trial treating smokers with AUD were randomly assigned to receive placebo, low-dose topiramate (up to 125 mg/day), or high-dose topiramate (up to 250 mg/day), along with brief behavioral compliance enhancement treatment. A subsample (n = 101) completed ERP assessments at baseline (1 week pre-medication) and week 5 (5 weeks on medication; 1 week pre-quit). We assessed the salience of pleasant, unpleasant, cigarette-related, alcohol-related, and neutral pictorial cues using the late positive potential (LPP) ERP component and measured self-reported substance use, reinforcement, craving, and withdrawal., Results: Five weeks of high-dose topiramate treatment decreased LPP amplitudes in response to both emotional (pleasant and unpleasant) and drug-related cues (alcohol and cigarette), but not to neutral cues. However, results showed that the LPPs were not significant mediators of the relationship between topiramate dose and post-quit measures of substance use, reinforcement, craving, or withdrawal., Conclusions: These findings suggest that high-dose topiramate (up to 250 mg/day) decreases the motivational salience of both drug-related and emotional cues among smokers with AUD. However, the nonsignificant mediation analyses preclude any firm conclusions about whether this effect represents one of topiramate's therapeutic mechanisms of action., (© 2022 by the Research Society on Alcoholism.)
- Published
- 2022
- Full Text
- View/download PDF
31. Feasibility of Mobile and Sensor Technology for Remote Monitoring in Cancer Care and Prevention.
- Author
-
Peterson SK, Basen-Engquist K, Demark-Wahnefried W, Prokhorov AV, Shinn EH, Martch SL, Beadle BM, Garden AS, Farcas E, Brandon Gunn G, Fuller CD, Morrison WH, Rosenthal DI, Phan J, Eng C, Cinciripini PM, Karam-Hage MA, Camero Garcia M, and Patrick K
- Subjects
- Feasibility Studies, Humans, Technology, Cancer Survivors, Deglutition Disorders prevention & control, Head and Neck Neoplasms
- Abstract
Objectives. Remote monitoring (RM) of health-related outcomes may optimize cancer care and prevention outside of clinic settings. CYCORE is a software-based system for collection and analyses of sensor and mobile data. We evaluated CYCORE's feasibility in studies assessing: (1) physical functioning in colorectal cancer (CRC) patients; (2) swallowing exercise adherence in head and neck cancer (HNC) patients during radiation therapy; and (3) tobacco use in cancer survivors post-tobacco treatment (TTP). Methods. Participants completed RM: for CRC, blood pressure, activity, GPS; for HNC, video of swallowing exercises; for TTP, expired carbon monoxide. Patient-reported outcomes were assessed daily. Results. For CRC, HNC and TTP, respectively, 50, 37, and 50 participants achieved 96%, 84%, 96% completion rates. Also, 91-100% rated ease and self-efficacy as highly favorable, 72-100% gave equivalent ratings for overall satisfaction, 72-93% had low/no data privacy concerns. Conclusion. RM was highly feasible and acceptable for patients across diverse use cases., (©2021 AMIA - All rights reserved.)
- Published
- 2022
32. Trajectories of motivation and self-efficacy during a smoking quit attempt: An ecological momentary assessment study.
- Author
-
Hopkins PD, Spears CA, Hoover DS, Li L, Cambron C, Potter LN, Cinciripini PM, Lam CY, and Wetter DW
- Subjects
- Ecological Momentary Assessment, Female, Humans, Male, Self Efficacy, Smoking, Motivation, Smoking Cessation
- Abstract
Objective: Conceptual models of addiction highlight self-efficacy and motivation as key variables important during a smoking quit attempt; however, recent research has primarily focused on self-efficacy. Given the importance of motivation in these models, a clearer understanding of the effects of motivation during a smoking quit attempt is needed., Method: This study utilized ecological momentary assessment (EMA) to investigate the dynamic effects of motivation and self-efficacy early in a quit attempt. Participants were 356 smokers (45% male; 34% African American, 33% non-Hispanic White, 33% Latino). Participants completed EMAs of motivation, self-efficacy, and smoking for 4 days prequit through 1 week postquit, and returned for a follow-up assessment at 4 weeks postquit. Trajectory parameters of motivation and self-efficacy (mean, slope, and volatility) were analyzed in separate and combined regression models to predict smoking outcomes., Results: Prequit results showed that parameters of motivation and self-efficacy were not associated with smoking on quit day. Postquit analyses revealed that participants with lower mean levels of motivation and self-efficacy were more likely to smoke at the end of Week 1. Moreover, individuals with decreasing levels of motivation over the first week of their quit attempt were more likely to be smoking at the end of Week 4., Conclusions: These findings highlight the need to incorporate dynamic measures of motivation in smoking research. Furthermore, the results underscore the value of utilizing EMA methods and trajectory parameters to gain a more nuanced understanding of the dynamic effects that key mechanisms have on smoking during a quit attempt. (PsycInfo Database Record (c) 2022 APA, all rights reserved).
- Published
- 2022
- Full Text
- View/download PDF
33. You Don't Need an App-Conducting Mobile Smoking Research Using a Qualtrics-Based Approach.
- Author
-
Cui Y, Robinson JD, Rymer RE, Minnix JA, and Cinciripini PM
- Abstract
With the increasing availability of smartphones, many tobacco researchers are exploring smartphone-delivered mobile smoking interventions as a disseminable means of treatment. Most effort has been focused on the development of smartphone applications (apps) to conduct mobile smoking research to implement and validate these interventions. However, developing project-specific smartphone apps that work across multiple mobile platforms (e.g., iOS and Android) can be costly and time-consuming. Here, using a hypothetical study, we present an alternate approach to demonstrate how mobile smoking cessation and outcome evaluation can be conducted without the need of a dedicated app. Our approach uses the Qualtrics platform, a popular online survey host that is used under license by many academic institutions. This platform allows researchers to conduct device-agnostic screening, consenting, and administration of questionnaires through Qualtrics's native survey engine. Researchers can also collect ecological momentary assessment data using text messaging prompts with the incorporation of Amazon Web Services' Pinpoint. Besides these assessment capabilities, Qualtrics has the potential for delivering personalized behavioral interventions through the use of JavaScript code. By customizing the question's web elements in Qualtrics (e.g., using texts, images, videos, and buttons), researchers can integrate interactive web-based interventions and complicated behavioral and cognitive tasks into the survey. In conclusion, this Qualtrics-based methodology represents a novel and cost-effective approach for conducting mobile smoking cessation and assessment research., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer CS declared a past collaboration with one of the authors PC to the handling editor., (Copyright © 2022 Cui, Robinson, Rymer, Minnix and Cinciripini.)
- Published
- 2022
- Full Text
- View/download PDF
34. Python Package abstcal: An Open-Source Tool for Calculating Abstinence From Timeline Followback Data.
- Author
-
Cui Y, Robinson JD, Rymer RE, Minnix JA, and Cinciripini PM
- Subjects
- Humans, Reproducibility of Results, Smoking, Smoking Cessation
- Abstract
Introduction: In smoking cessation clinical trials, timeline followback (TLFB) interviews are widely used to track daily cigarette consumption. However, there are no standard tools for calculating abstinence based on TLFB data. Individual research groups have to develop their own calculation tools, which is not only time- and resource-consuming but might also lead to variability in the data processing and calculation procedures., Aims and Methods: To address these issues, we developed a novel open-source Python package named abstcal to calculate abstinence using TLFB data. This package provides data verification, duplicate and outlier detection, missing-data imputation, integration of biochemical verification data, and calculation of a variety of definitions of abstinence, including continuous, point-prevalence, and prolonged abstinence., Results: We verified the accuracy of the calculator using data derived from a clinical smoking cessation study. To improve the package's accessibility, we have made it available as a free web app., Conclusions: The abstcal package is a reliable abstinence calculator with open-source access, providing a shared validated online tool to the addiction research field. We expect that this open-source abstinence calculation tool will improve the rigor and reproducibility of smoking and addiction research by standardizing TLFB-based abstinence calculation., Implications: Abstinence calculation is an essential task in any smoking intervention study. However, there have not been standard open-source tools available to the researchers. This commentary describes a Python-based package called abstcal that can calculate abstinence from TLFB data, a common methodology to collect smoking consumption data in research settings. The package supports the calculation of point-prevalence, prolonged, and continuous abstinence. Importantly, the package has a web app interface that allows researchers to use the tool without any coding experience. This tool will facilitate smoking research by providing a standardized and easy-to-use abstinence calculation tool., (© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
35. A Comprehensive Program to Reduce Tobacco-related Cancers Through Actions by a National Cancer Institute-designated Cancer Center.
- Author
-
Cofer J, Hurst AN, Winter T, Moreno M, Cinciripini PM, Walsh MT Jr, Tektiridis J, and Hawk E
- Subjects
- Adult, Adolescent, United States epidemiology, Humans, National Cancer Institute (U.S.), Smoking, Nicotiana, Delivery of Health Care, Tobacco Use Disorder prevention & control, Neoplasms epidemiology, Neoplasms prevention & control
- Abstract
Tobacco use accounts for 30% of all cancer-related deaths worldwide and 20% in the US, despite effective, evidence-based interventions for reducing tobacco use and tobacco-related cancers and deaths. In 2012, to reduce the burden of tobacco-related cancer and associated population-level risks across Texas, The University of Texas MD Anderson Cancer Center initiated the EndTobacco
® program to promote statewide cancer control activities. We created evidence-based initiatives, established selection criteria, and implemented actions involving policy, education, and tobacco treatment services. As a result, EndTobacco has supported, educated, and convened local and state coalitions in policymaking; provided tobacco treatment education to health professionals; implemented Texas' only certified tobacco treatment training program; and led an initiative to enhance the tobacco-free culture of the state's publicly funded university system. Supported by commitments from MD Anderson, we developed and implemented evidence-based actions for tobacco control tailored to the center's mission, values, expertise, resources, and partnerships. By 2021, the adult smoking rate in Texas dropped from 19.2% (2014) to 13.2%. Contributors to this drop include state tobacco control policies, programs and services from multiple agencies and associations, and EndTobacco activities that complement the statewide effort to prevent youth smoking initiation and increase quit attempts among youth and adults.- Published
- 2022
- Full Text
- View/download PDF
36. Predictors of Enrollment of Older Smokers in Six Smoking Cessation Trials in the Lung Cancer Screening Setting: The Smoking Cessation at Lung Examination (SCALE) Collaboration.
- Author
-
Eyestone E, Williams RM, Luta G, Kim E, Toll BA, Rojewski A, Neil J, Cinciripini PM, Cordon M, Foley K, Haas JS, Joseph AM, Minnix JA, Ostroff JS, Park E, Rigotti N, Sorgen L, and Taylor KL
- Subjects
- Early Detection of Cancer, Humans, Lung, Randomized Controlled Trials as Topic, Smokers, Lung Neoplasms diagnosis, Lung Neoplasms epidemiology, Smoking Cessation
- Abstract
Significance: Increased rates of smoking cessation will be essential to maximize the population benefit of low-dose CT screening for lung cancer. The NCI's Smoking Cessation at Lung Examination (SCALE) Collaboration includes eight randomized trials, each assessing evidence-based interventions among smokers undergoing lung cancer screening (LCS). We examined predictors of trial enrollment to improve future outreach efforts for cessation interventions offered to older smokers in this and other clinical settings., Methods: We included the six SCALE trials that randomized individual participants. We assessed demographics, intervention modalities, LCS site and trial administration characteristics, and reasons for declining., Results: Of 6285 trial- and LCS-eligible individuals, 3897 (62%) declined and 2388 (38%) enrolled. In multivariable logistic regression analyses, Blacks had higher enrollment rates (OR 1.5, 95% CI 1.2,1.8) compared to Whites. Compared to "NRT Only" trials, those approached for "NRT + prescription medication" trials had higher odds of enrollment (OR 6.1, 95% CI 4.7,7.9). Regarding enrollment methods, trials using "Phone + In Person" methods had higher odds of enrollment (OR 1.6, 95% CI 1.2,1.9) compared to trials using "Phone Only" methods. Some of the reasons for declining enrollment included "too busy" (36.6%), "not ready to quit" (8.2%), "not interested in research" (7.7%), and "not interested in the intervention offered" (6.2%)., Conclusion: Enrolling smokers in cessation interventions in the LCS setting is a major priority that requires multiple enrollment and intervention modalities. Barriers to enrollment provide insights that can be addressed and applied to future cessation interventions to improve implementation in LCS and other clinical settings with older smokers., Implications: We explored enrollment rates and reasons for declining across six smoking cessation trials in the lung cancer screening setting. Offering multiple accrual methods and pharmacotherapy options predicted increased enrollment across trials. Enrollment rates were also greater among Blacks compared to Whites. The findings offer practical information for the implementation of cessation trials and interventions in the lung cancer screening context and other clinical settings, regarding intervention modalities that may be most appealing to older, long-term smokers., (© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved.For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
37. Behavioral Economic Assessment of Alcohol and Cigarette Demand in Smokers With Alcohol Use Disorder.
- Author
-
Cui Y, Linares Abrego P, Yoon JH, Karam-Hage M, Cinciripini PM, Ait-Daoud Tiouririne N, Anthenelli RM, and Robinson JD
- Abstract
Background and Objectives: Behavioral economic purchase tasks are widely used to assess drug demand in substance use disorder research. Comorbid alcohol use is common among cigarette smokers and associated with greater difficulty in quitting smoking. However, demand for alcohol and cigarettes in this population has not been fully characterized. The present study addressed this gap by examining alcohol and cigarette demand among treatment-seeking smokers with alcohol use disorder (AUD). Methods: Alcohol and cigarette demand was assessed among 99 smokers with AUD. We conducted Principal Component Analysis (PCA) and correlational analyses on the demand indices. Results: Participants showed higher demand for alcohol than for cigarettes, as evidenced lower elasticity (resistance to increasing price) and higher O
max (maximum response output for drug). PCA revealed a two-factor structure (Persistence and Amplitude) for both alcohol and cigarette demand indices. Cigarette-related demand indices were positively correlated with nicotine dependence, but alcohol-related demand indices were not associated with alcohol dependence, suggesting dissociation between alcohol demand and use behaviors. Discussion and Conclusions: Our results suggest that smokers with AUD were more resistant to price elevations in relation to reducing alcohol consumption as compared to cigarette consumption, suggesting preferential demand for alcohol over cigarettes. However, it is unclear how acute substance exposure/withdrawal impacts the demand indices. Scientific Significance: Potentially differential alcohol and cigarette demands among smokers with AUD should be considered in the concurrent treatment of smoking and alcohol., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Cui, Linares Abrego, Yoon, Karam-Hage, Cinciripini, Ait-Daoud Tiouririne, Anthenelli and Robinson.)- Published
- 2021
- Full Text
- View/download PDF
38. Cross-sectional survey for assessing cancer care providers' characteristics and attitudes on smoking cessation in Colombia and Mexico.
- Author
-
Tami-Maury I, Suchil L, Reynales-Shigematsu LM, Garcia-Gomez L, Chen M, Shete S, Betancur A, Cinciripini PM, Hawk E, and Garcia H
- Subjects
- Adult, Attitude, Colombia epidemiology, Cross-Sectional Studies, Humans, Mexico epidemiology, Quality of Life, Surveys and Questionnaires, Neoplasms epidemiology, Neoplasms therapy, Smoking Cessation
- Abstract
Objective: Cancer care providers' (CCPs) attitudes towards smoking cessation are influenced by many factors, including their smoking status and knowledge. Our objective was to assess CCPs' characteristics, tobacco use and smoking cessation practices in two Latin American cancer centres., Design: Cross-sectional survey., Settings: Two urban cancer centres located in Colombia and Mexico., Participants: A total of 238 CCPs., Measures: Online survey consisted of 28 close-ended questions adapted from the 2012 International Association for the Study of Lung Cancer survey and the Global Adult Tobacco Survey developed by the WHO. Means, frequencies and proportions were reported for each country. Factors associated to providing of smoking cessation treatment or referral at initial visit were evaluated using logistic regression., Results: Current smoking prevalence was 10.5% and 12.3% among Colombian and Mexican CCPs, respectively. Around three quarters of the Colombian (86.4%) and Mexican CCPs (66.1%) considered to have inadequate training in smoking cessation. Approximately two-thirds of Colombian (67.5%) and Mexican CCPs (63.9%) reported always or most of the time asking patients about tobacco use during the initial visit. In Colombia and Mexico, the most relevant barriers for providing cessation services were (1) difficulties for motivating patients with cancer, (2) patient resistance in quitting smoking, (3) lack of local resources or referral centres for smoking cessation and (4) lack of training in smoking cessation. CCPs appointed at Instituto Nacional de Cancerología were less likely to provide cessation treatment or referral to their patients if they had less than 50% of their time devoted to patient care and were former or current smokers. The regression model for Instituto de Cancerología did not retain statistically significant variables., Conclusion: Our findings highlight an urgent need for assisting Latin American CCPs in their quitting efforts as well as expanding formal smoking cessation training specifically tailored to these professionals for improving patients' cancer prognosis and quality of life., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
39. Smoking cessation and shared decision-making practices about lung cancer screening among primary care providers.
- Author
-
Lopez-Olivo MA, Minnix JA, Fox JG, Nishi SPE, Lowenstein LM, Maki KG, Leal VB, Tina Shih YC, Cinciripini PM, and Volk RJ
- Subjects
- Aged, Communication, Counseling methods, Female, Follow-Up Studies, Health Personnel psychology, Humans, Lung Neoplasms epidemiology, Lung Neoplasms prevention & control, Male, Middle Aged, Patient Education as Topic, Primary Health Care, Prognosis, Smoking epidemiology, Smoking Cessation statistics & numerical data, Surveys and Questionnaires, Texas epidemiology, Decision Making, Shared, Early Detection of Cancer methods, Lung Neoplasms diagnosis, Practice Patterns, Physicians', Smoking therapy, Smoking Cessation methods
- Abstract
Objective: We describe primary care providers' current practice patterns related to smoking cessation counseling and lung cancer screening (LCS)., Methods: Family, internal medicine, and pulmonary medicine providers from two medical centers were asked to complete an electronic survey to report their practice patterns., Results: Of 52 participating providers, most reported initiating three major components of a smoking cessation intervention often or very often: advise to quit (50, 96%), assess willingness to quit (47, 90%), and assist with counseling or pharmacotherapy (49, 94%). However, other components were less commonly initiated such as arranging follow-ups (only 11 providers indicated recommending them often or very often, 21%) and less than half of providers reported that they often or very often recommend cessation counseling or pharmacotherapy of any type (except varenicline), though family medicine providers were more likely to recommend pharmacotherapy compared to the other specialists (p < 0.01). The majority of providers (47, 92%) reported that they engage in informed/shared decision-making about LCS, although only about one-third (17, 33%) indicated using a patient decision aid. Pulmonary medicine providers were more likely to use decision aids than providers from internal or family medicine (p < 0.04)., Conclusions: Within the context of LCS, primary care providers report often having conversations about smoking cessation with their patients who smoke, have no clear preference for type of treatment, and rarely use follow-up calls or visits pertaining to quitting smoking. While many providers report engaging in shared decision-making about LCS, few use a decision aid for this conversation., (© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
40. Impact of the COVID-19 pandemic on telehealth research in cancer prevention and care: A call to sustain telehealth advances.
- Author
-
Park ER, Chiles C, Cinciripini PM, Foley KL, Fucito LM, Haas JS, Joseph AM, Ostroff JS, Rigotti NA, Shelley DR, Taylor KL, Zeliadt SB, and Toll BA
- Subjects
- Confidentiality, Delivery of Health Care, Humans, Lung diagnostic imaging, Lung Neoplasms diagnostic imaging, Lung Neoplasms etiology, Neoplasms diagnostic imaging, Neoplasms therapy, Patient Participation, Smoking Cessation, Tomography, X-Ray Computed, Biomedical Research methods, COVID-19, Neoplasms prevention & control, Telemedicine methods, Telemedicine organization & administration
- Published
- 2021
- Full Text
- View/download PDF
41. Intersectionality and Smoking Cessation: Exploring Various Approaches for Understanding Health Inequities.
- Author
-
Potter LN, Lam CY, Cinciripini PM, and Wetter DW
- Subjects
- Adult, Female, Humans, Income, Longitudinal Studies, Male, Smoking ethnology, Smoking psychology, Smoking Cessation methods, Smoking Cessation psychology, Social Class, Ethnicity psychology, Health Behavior, Health Status Disparities, Smoking therapy, Smoking Cessation ethnology
- Abstract
Objective: Many marginalized groups smoke at higher rates and have greater difficulty quitting than less marginalized groups. Most research on smoking cessation inequities has focused on a single sociodemographic attribute (eg, race or socioeconomic status), yet individuals possess multiple attributes that may increase risk. The current study used an intersectionality framework to examine how the interplay between multiple marginalized attributes may impact smoking cessation outcomes., Methods: A diverse sample of 344 adults enrolled in a smoking cessation program and reported on sociodemographic attributes (eg, race/ethnicity, gender, income) and continuous smoking abstinence on their quit date and at 1, 2, and 4 weeks postquit date. A Cox proportional hazard regression model was used to estimate whether intersectional links among race/ethnicity, gender, and income were related to smoking cessation outcomes., Results: Lower household income may be related to higher risk of smoking cessation failure. There were no significant interactions among race/ethnicity, gender, and income in predicting relapse. Pairwise intersectional group differences suggested some groups may be at higher risk of relapse. Number of marginalized sociodemographic attributes did not predict relapse., Conclusions: Intersectionality may be a promising framework for addressing health inequities, and may help elucidate how to best design and target intervention efforts for individuals characterized by sociodemographic intersections that concur particularly high risk for poor tobacco cessation outcomes., Implications: Despite an overall decline in smoking rates, socioeconomic inequities in smoking prevalence and cancer mortality are widening. Efforts targeting tobacco cessation should incorporate new theory to capture the complex set of factors that may account for tobacco cessation inequities (eg, multiple aspects of identity that may influence access to tobacco cessation treatment and exposure to certain stressors that impede cessation efforts). Intersectionality may be a promising framework for addressing health inequities in tobacco use and cessation and may help elucidate how to best design and target intervention efforts for individuals that concur particularly high risk for poor tobacco cessation outcomes., (© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved.For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
42. A time-varying model of the dynamics of smoking lapse.
- Author
-
Potter LN, Haaland BA, Lam CY, Cambron C, Schlechter CR, Cinciripini PM, and Wetter DW
- Subjects
- Adult, Female, Humans, Male, Motivation, Risk Factors, Time Factors, Smoking psychology, Smoking Cessation methods
- Abstract
Objective: The majority of smokers who make a quit attempt experience their first lapse within the first week of quitting, yet limited research to date has examined how the strength and direction of the relationship between smoking risk factors and lapse may change over longer periods of time. Time-varying effect modeling (TVEM) was used to address this gap., Method: A diverse sample (N = 325) of adult smokers completed ecological momentary assessments of risk factors for lapse for 28 days after quitting. TVEM was used to examine the relationship between risk factors (abstinence self-efficacy, positive affect, positive coping expectancies, smoking expectancies, motivation, negative affect, stress, and urge) and lapse for 28 days postquit., Results: Some associations were stable (e.g., negative affect, motivation), whereas others varied over time. Abstinence self-efficacy, positive affect, and positive coping expectancies were most strongly associated with lapse between Days 3 and 8 postquit. The association of urge with lapse was strongest between Days 4 and 10, as well as near the end of the quit attempt. Stress was also most strongly associated with lapse near the beginning and end of the postquit period and was the only predictor associated with lapse on quit date. The strength of the association between smoking expectancies and lapse increased over time., Conclusion: There may be periods during a quit attempt when certain risk factors are more strongly related to lapse. This work has relevance for tailoring interventions designed to deliver intervention components in particular contexts or times of need. (PsycInfo Database Record (c) 2020 APA, all rights reserved).
- Published
- 2021
- Full Text
- View/download PDF
43. Very Low Nicotine Content Cigarettes Disrupt the Feedback Loop of Affective States and Smoking Behavior.
- Author
-
Robinson JD, Kypriotakis G, Al'absi M, Denlinger-Apte RL, Drobes DJ, Leischow SJ, McClernon FJ, Pacek LR, Severson HH, Smith TT, Donny EC, Luo X, Jensen JA, Strayer LG, Cinciripini PM, and Hatsukami DK
- Subjects
- Adolescent, Adult, Case-Control Studies, Cigarette Smoking epidemiology, Double-Blind Method, Emotions, Female, Humans, Male, Motivation, Nicotine administration & dosage, Smoking Cessation methods, Tobacco Products statistics & numerical data, United States epidemiology, Young Adult, Cigarette Smoking psychology, Feedback, Nicotine analysis, Reinforcement, Psychology, Smokers psychology, Smoking psychology, Tobacco Use Disorder psychology
- Abstract
Introduction: Smoking to reduce negative affect has been identified as a key motivational feature of tobacco use. Our recent work suggests that smoking very low nicotine content (VLNC) cigarettes reduces the relationship between negative affect and smoking behavior over a 6-week period. Here, we sought to extend our findings by evaluating whether a gradual or immediate approach to switching to VLNC cigarettes led to a differential reduction in the relationship between affect and smoking behavior over a longer (20-week) period., Aims and Methods: Participants (n = 1250) were adult smokers from 10 US sites randomized to one of three groups: gradual nicotine reduction (15.5, 11.7, 5.2, 2.4, and 0.4 mg of nicotine per gram of tobacco [mg/g]), immediate nicotine reduction (0.4 mg/g), or standard nicotine content cigarettes (15.5 mg/g; control), for 20 weeks. We examined whether the relationship between affect-both negative and positive-and cigarettes per day differed as a function of reduction group., Results: We found that both negative and positive affect were associated with cigarette consumption in the control group, but not in the gradual or immediate reduction groups across the 20 weeks of exposure., Conclusions: Our results extend previous findings that switching to VLNC cigarettes disrupts the relationship between affect and cigarette consumption by showing that either gradually or immediately reducing cigarette nicotine content achieves this disruption. These findings provide further evidence that switching to VLNC cigarettes reduces nicotine-related reinforcement of cigarette smoking., Implications: These findings support the notion that switching to very low nicotine content cigarettes reduces the association between affect and smoking behavior, and that either a gradual or immediate nicotine reduction approach achieves this reduction. This provides further evidence that switching to very low nicotine content cigarettes weakens reinforcement mechanisms associated with nicotine dependence., (© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
44. Toward Precision Medicine for Smoking Cessation: Developing a Neuroimaging-Based Classification Algorithm to Identify Smokers at Higher Risk for Relapse.
- Author
-
Frank DW, Cinciripini PM, Deweese MM, Karam-Hage M, Kypriotakis G, Lerman C, Robinson JD, Tyndale RF, Vidrine DJ, and Versace F
- Subjects
- Female, Humans, Male, Middle Aged, Recurrence, Smoking Cessation methods, Tobacco Use Disorder epidemiology, Tobacco Use Disorder psychology, United States epidemiology, Algorithms, Neuroimaging methods, Precision Medicine, Smokers psychology, Smoking Cessation statistics & numerical data, Tobacco Use Disorder diagnosis
- Abstract
Introduction: By improving our understanding of the neurobiological mechanisms underlying addiction, neuroimaging research is helping to identify new targets for personalized treatment interventions. When trying to quit, smokers with larger electrophysiological responses to cigarette-related, compared with pleasant, stimuli ("C > P") are more likely to relapse than smokers with the opposite brain reactivity profile ("P > C")., Aim and Method: The goal was to (1) build a classification algorithm to identify smokers characterized by P > C or C > P neuroaffective profiles and (2) validate the algorithm's classification outcomes in an independent data set where we assessed both smokers' electrophysiological responses at baseline and smoking abstinence during a quit attempt. We built the classification algorithm applying discriminant function analysis on the event-related potentials evoked by emotional images in 180 smokers., Results: The predictive validity of the classifier showed promise in an independent data set that included new data from 177 smokers interested in quitting; the algorithm classified 111 smokers as P > C and 66 as C > P. The overall abstinence rate was low; 15 individuals (8.5% of the sample) achieved CO-verified 12-month abstinence. Although individuals classified as P > C were nearly 2.5 times more likely to be abstinent than smokers classified as C > P (12 vs. 3, or 11% vs. 4.5%), this result was nonsignificant, preliminary, and in need of confirmation in larger trials., Conclusion: These results suggest that psychophysiological techniques have the potential to advance our knowledge of the neurobiological underpinnings of nicotine addiction and improve clinical applications. However, larger sample sizes are necessary to reliably assess the predictive ability of our algorithm., Implications: We assessed the clinical relevance of a neuroimaging-based classification algorithm on an independent sample of smokers enrolled in a smoking cessation trial and found those with the tendency to attribute more relevance to rewards than cues were nearly 2.5 times more likely to be abstinent than smokers with the opposite brain reactivity profile (11% vs. 4.5%). Although this result was not statistically significant, it suggests our neuroimaging-based classification algorithm can potentially contribute to the development of new precision medicine interventions aimed at treating substance use disorders. Regardless, these findings are still preliminary and in need of confirmation in larger trials., (© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
45. Modeling neuroaffective biomarkers of drug addiction: A Bayesian nonparametric approach using dirichlet process mixtures.
- Author
-
Kypriotakis G, Cinciripini PM, and Versace F
- Subjects
- Bayes Theorem, Biomarkers, Humans, Reproducibility of Results, Smoking, Substance-Related Disorders
- Abstract
Background: The properties of neurophysiological processes related to addiction have received much attention in the literature. However, empirical evidence of meaningful and useful characterization of these processes is limited. Recent studies have found that electrophysiological responses to emotional and drug-related cues can be used to create profiles that reliably predict smoking relapse., New Method: This paper evaluates the validity of classifying electrophysiological responses into distinct profiles using a Bayesian dirichlet process mixture (DPM) model. The DPM is a Bayesian nonparametric (BNP) method to modeling unknown number of profiles characterized by uncertainty in cluster membership and in cluster number., Results: The DPM model confirmed previously identified neuroaffective reactivity profiles, but also revealed a finer level of granularity in the clustering. Specifically, in addition to the two clusters previously identified in the literature, the BNP methods identified a cluster of individuals showing similar responses to smoking, pleasant, neutral and unpleasant cues., Comparison With Existing Methods: BNP models provide an alternative to the k-mean clustering approach to modeling EEG-based neuroaffective profiles. Unlike k-means clustering, BNP models compute the probability that a subject belongs to a cluster while taking into consideration uncertainty in the number of clusters., Conclusions: Our results confirm the reliability of the two clusters previously identified in these data, but also provide new insights by revealing a cluster that presented similar responses to stimuli with different contents. This finding may be related to the uncertainty in classification or overlapping brain-reactivity profiles., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
46. Pragmatic Application of the RE-AIM Framework to Evaluate the Implementation of Tobacco Cessation Programs Within NCI-Designated Cancer Centers.
- Author
-
D'Angelo H, Ramsey AT, Rolland B, Chen LS, Bernstein SL, Fucito LM, Webb Hooper M, Adsit R, Pauk D, Rosenblum MS, Cinciripini PM, Joseph A, Ostroff JS, Warren GW, Fiore MC, and Baker TB
- Subjects
- Humans, National Cancer Institute (U.S.), Smokers, United States, Neoplasms, Smoking Cessation, Tobacco Use Cessation, Tobacco Use Disorder
- Abstract
Tobacco cessation after cancer diagnosis leads to better patient outcomes. However, tobacco treatment services are frequently unavailable in cancer care settings, and multilevel implementation challenges can impede uptake of new programs. The National Cancer Institute (NCI) dedicated Cancer Moonshot funding through the Cancer Center Cessation Initiative (C3I) for NCI-Designated Cancer Centers to implement or enhance the implementation of tobacco treatment services. We examined a pragmatic application of the RE-AIM framework (reach, effectiveness, adoption, implementation, and maintenance) to evaluate tobacco treatment programs implemented within Cancer Centers funded through C3I. Using three C3I-funded Centers as examples, we describe how each RE-AIM construct was operationalized to evaluate the implementation of a wide range of cessation services (e.g., tobacco use screening, counseling, Quitline referral, pharmacotherapy) in this heterogeneous group of cancer care settings. We discuss the practical challenges encountered in assessing RE-AIM constructs in real world situations, including using the electronic health record (EHR) to aid in assessment. Reach and effectiveness evaluation required that Centers define the setting(s) where cessation services were implemented (to determine the "denominator"), enumerate the patient population, report current patient tobacco use, patient engagement in tobacco treatment, and 6-month cessation outcomes. To reduce site heterogeneity, increase data accuracy, and reduce burden, reach was frequently captured via standardized EHR enhancements that improved the identification of current smokers and tobacco treatment referrals. Effectiveness was determined by cessation outcomes (30-day point prevalence abstinence at 6-months post-engagement) assessed through a variety of data collection approaches. Adoption was measured by the characteristics and proportion of targeted cancer care settings and clinicians engaged in cessation service delivery. Implementation was assessed by examining the delivery of tobacco screening assessments and intervention components across sites, and provider-level implementation consistency. Maintenance assessments identified whether tobacco treatment services continued in the setting after implementation and documented the sustainability plan and organizational commitment to continued delivery. In sum, this paper demonstrates a pragmatic approach to using RE-AIM as an evaluation framework that yields relevant outcomes on common implementation metrics across widely differing tobacco treatment approaches and settings., (Copyright © 2020 D'Angelo, Ramsey, Rolland, Chen, Bernstein, Fucito, Webb Hooper, Adsit, Pauk, Rosenblum, Cinciripini, Joseph, Ostroff, Warren, Fiore and Baker.)
- Published
- 2020
- Full Text
- View/download PDF
47. Withdrawal Symptom, Treatment Mechanism, and/or Side Effect? Developing an Explicit Measurement Model for Smoking Cessation Research.
- Author
-
Tonkin SS, Williams TF, Simms LJ, Tiffany ST, Mahoney MC, Schnoll RA, Cinciripini PM, and Hawk LW
- Subjects
- Humans, Surveys and Questionnaires, Craving physiology, Drug-Related Side Effects and Adverse Reactions etiology, Models, Statistical, Smoking adverse effects, Smoking psychology, Smoking Cessation psychology, Substance Withdrawal Syndrome drug therapy, Tobacco Use Disorder therapy
- Abstract
Introduction: Assessment of withdrawal symptoms, treatment mechanisms, and side effects is central to understanding and improving smoking cessation interventions. Though each domain is typically assessed separately with widely used questionnaires to separately assess each domain (eg, Minnesota Nicotine Withdrawal Scale = withdrawal; Questionnaire of Smoking Urges-Brief = craving; Positive and Negative Affect Schedule = affect; symptom checklist = side effects), there are substantial problems with this implicit "one questionnaire equals one construct" measurement model, including item overlap across questionnaires. This study sought to clarify the number and nature of constructs assessed during smoking cessation by developing an explicit measurement model., Methods: Two subsamples were randomly created from 1246 smokers in a clinical trial. Exploratory and confirmatory factor analyses were conducted to identify and select a model that best represented the data. Measurement invariance was assessed to determine if the factors and their content were consistent prior to and during the quit. Improvement in construct overlap within this model was compared against the implicit measurement model using correlational analyses., Results: A 5-factor measurement model composed of negative affect, somatic symptoms, sleep problems, positive affect, and craving fits the data well prior to and during quitting. All factor content except somatic symptoms was consistent over time. Correlational analyses indicated that the 5-factor model attenuated construct overlap compared to the implicit model., Conclusions: The models generated from data-driven approaches (eg, the 5-factor model) reduced overlap and better represented the constructs underlying these measures. This approach created distinct, stable constructs that span over measures of side effects and potential treatment mechanisms., Implications: This study demonstrated that measures assessing treatment mechanisms, withdrawal symptoms, and side effects contain problematic overlap that reduces the clarity of these key constructs. The use of data-driven approaches showed that these measures do not map on to their posited latent constructs (eg, the Minnesota Nicotine Withdrawal Scale does not yield a withdrawal factor). Rather, these measures form distinct, basic processes that may represent more meaningful constructs for future research on cessation and treatment. Assessments designed to individually examine these processes may improve the study of treatment mechanisms., (© The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
48. Estimating statistical power for event-related potential studies using the late positive potential.
- Author
-
Gibney KD, Kypriotakis G, Cinciripini PM, Robinson JD, Minnix JA, and Versace F
- Subjects
- Adult, Emotions physiology, Female, Humans, Male, Middle Aged, Models, Statistical, Monte Carlo Method, Pattern Recognition, Visual physiology, Data Interpretation, Statistical, Electroencephalography statistics & numerical data, Evoked Potentials physiology, Research Design statistics & numerical data
- Abstract
The late positive potential (LPP) is a common measurement used to study emotional processes of subjects in ERP paradigms. Despite its extensive use in affective neuroscience, there is presently no gold standard for how to appropriately power ERP studies using the LPP. The present study investigates how the number of trials, number of subjects, and magnitude of the effect size affect statistical power in analyses of the LPP. Using Monte Carlo simulations of ERP experiments with varying numbers of trials, subjects, and synthetic effects of known magnitude, we measured the probability of obtaining a statistically significant effect in 1,489 experiments repeated 1,000 times each. Predictably, our results showed that statistical power increases with increasing numbers of trials and subjects and at larger effect sizes. We also found that higher levels of statistical power can be achieved with lower numbers of subjects and trials and at lower effect sizes in within-subject than in between-subjects designs. Furthermore, we found that, as subjects are added to an experiment, the slope of the relationship between effect size and statistical power increased and shifted to the left until the power asymptoted to nearly 100% at higher effect sizes. This suggests that adding more subjects greatly increases statistical power at lower effect sizes (<1 µV) compared with more robust (>1.5 µV) effect sizes. We confirmed the results from the simulations based on the synthetic effects by running a new series of simulated experiments based on real data collected while participants looked at emotional images., (© 2019 Society for Psychophysiological Research.)
- Published
- 2020
- Full Text
- View/download PDF
49. Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: A Randomized Clinical Trial.
- Author
-
Volk RJ, Lowenstein LM, Leal VB, Escoto KH, Cantor SB, Munden RF, Rabius VA, Bailey L, Cinciripini PM, Lin H, Housten AJ, Luckett PG, Esparza A, Godoy MC, and Bevers TB
- Subjects
- Adult, Aged, Aged, 80 and over, Decision Support Techniques, Female, Humans, Male, Mass Screening statistics & numerical data, Middle Aged, Patient Participation statistics & numerical data, Tomography, X-Ray Computed statistics & numerical data, United States, Early Detection of Cancer methods, Early Detection of Cancer psychology, Lung Neoplasms diagnosis, Mass Screening psychology, Patient Participation psychology, Smokers psychology, Smokers statistics & numerical data, Tomography, X-Ray Computed psychology
- Abstract
Importance: Lung cancer screening with low-dose computed tomography lowers lung cancer mortality but has potential harms. Current guidelines support patients receiving information about the benefits and harms of lung cancer screening during decision-making., Objective: To examine the effect of a patient decision aid (PDA) about lung cancer screening compared with a standard educational material (EDU) on decision-making outcomes among smokers., Design, Setting, and Participants: This randomized clinical trial was conducted using 13 state tobacco quitlines. Current and recent tobacco quitline clients who met age and smoking history eligibility for lung cancer screening were enrolled from March 30, 2015, to September 12, 2016, and followed up for 6 months until May 5, 2017. Data analysis was conducted between May 5, 2017, and September 30, 2018., Interventions: Participants were randomized to the PDA video Lung Cancer Screening: Is It Right for Me? (n = 259) or to EDU (n = 257)., Main Outcomes and Measures: The primary outcomes were preparation for decision-making and decisional conflict measured at 1 week. Secondary outcomes included knowledge, intentions, and completion of screening within 6 months of receiving the intervention measured by patient report., Results: Of 516 quit line clients enrolled, 370 (71.7%) were younger than 65 years, 320 (62.0%) were female, 138 (26.7%) identified as black, 47 (9.1%) did not have health insurance, and 226 (43.8%) had a high school or lower educational level. Of participants using the PDA, 153 of 227 (67.4%) were well prepared to make a screening decision compared with 108 of 224 participants (48.2%) using EDU (odds ratio [OR], 2.31; 95% CI, 1.56-3.44; P < .001). Feeling informed about their screening choice was reported by 117 of 234 participants (50.0%) using a PDA compared with 66 of 233 participants (28.3%) using EDU (OR, 2.56; 95% CI, 1.72-3.79; P < .001); 159 of 234 participants (68.0%) using a PDA compared with 110 of 232 (47.4%) participants using EDU reported being clear about their values related to the harms and benefits of screening (OR, 2.37; 95% CI, 1.60-3.51; P < .001). Participants using a PDA were more knowledgeable about lung cancer screening than participants using EDU at each follow-up assessment. Intentions to be screened and screening behaviors did not differ between groups., Conclusions and Relevance: In this study, a PDA delivered to clients of tobacco quit lines improved informed decision-making about lung cancer screening. Many smokers eligible for lung cancer screening can be reached through tobacco quit lines., Trial Registration: ClinicalTrials.gov identifier: NCT02286713.
- Published
- 2020
- Full Text
- View/download PDF
50. The impact of nicotine dose and instructed dose on smokers' implicit attitudes to smoking cues: An ERP study.
- Author
-
Cui Y, Engelmann JM, Gilbert DG, Waters AJ, Cinciripini PM, and Robinson JD
- Subjects
- Adult, Affect drug effects, Affect physiology, Attention drug effects, Brain drug effects, Brain physiopathology, Electroencephalography, Emotions drug effects, Emotions physiology, Evoked Potentials physiology, Female, Humans, Male, Middle Aged, Motivation drug effects, Motivation physiology, Reaction Time drug effects, Reaction Time physiology, Smoking physiopathology, Smoking psychology, Attention physiology, Attitude, Cues, Evoked Potentials drug effects, Nicotine administration & dosage, Smokers psychology
- Abstract
It is unclear whether nicotine and perceived nicotine exposure can influence automatic evaluations of cigarette stimuli. In the present study, we investigated the effects of nicotine dose and instructed dose on motivational responses to smoking cues. Forty overnight nicotine-deprived smokers completed an Implicit Association Test (IAT) at each of the four laboratory sessions in a balanced-placebo design that crossed nicotine dose (Given-NIC [given nicotine] vs. Given-DENIC [given denicotinized]) with instructed dose expectancy (Told-NIC [told-nicotine] vs. Told-DENIC. [told-denicotinized]). We measured participants' behavioral performance, including reaction time (RT) and accuracy rate, and the early posterior negativity (EPN) component using the event-related potential (ERP) technique to the target pictures. During congruent trials when the categorization condition was smoking or unpleasant, smokers had greater classification accuracy, shorter RT latency, and greater EPN amplitudes compared to the incongruent trials when the categorization condition was smoking or pleasant. The Given-NIC condition was associated with increased classification accuracy, longer RT latency, and decreased EPN amplitudes compared to the Given-DENIC condition. Similarly, the Told-NIC condition was associated with increased accuracy and decreased EPN amplitudes compared to the Told-DENIC condition, but with shorter RT latency. Cigarette-related pictures produced greater EPN amplitudes than neutral pictures. Both behavioral and ERP results suggest that smokers have negative implicit attitudes toward smoking. While both nicotine dose and expected dose facilitated stimulus categorization, there was no evidence that either factor altered smokers' negative attitudes toward smoking cues. (PsycINFO Database Record (c) 2019 APA, all rights reserved).
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.